Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1143

Shown on this page

Current sort

Live official records

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 16
States / cities: Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more

Conditions: Colonic Neoplasms
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Urbana, Illinois • Boston, Massachusetts + 8 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older
Enrollment: 3,606 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Cancer
Interventions: Magnetic Resonance Imaging (MRI) Scan, Tc-99m Pentetate; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Enteric Hyperoxaluria
Interventions: Moderately High Oxalate (MOx) Diet; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 3,600 participants
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Substance Use
Interventions: Education and support for primary care providers (PCPS), Nurse Care Manager (NCM) visits, Addiction specialist consultant, Health coaching sessions, Patient educational materials; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Torrance, California • New York, New York • Enterprise, Oregon + 4 more

Conditions: Amputation; Lower Extremity, Pain, Persistent Postsurgical
Interventions: Surgical Implantation; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Overdose, Substance Use
Interventions: TA Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 2,940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: University of Sydney; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 19
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more

Conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more

About this NYU Langone Health institution page

What this page lists: ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NYU Langone Health

Filter and sort this campus

Live official records

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Lung Cancer Biomarkers and Screening

Advanced Diffusion Imaging in Renal Cancer Patients

Gut Kidney Axis in Enteric Hyperoxaluria

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNI

Permanent Supportive Housing Overdose Prevention+ Study

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

PF-07104091 as a Single Agent and in Combination Therapy

About this NYU Langone Health institution page